Fertility warning
This medicine may affect fertility.
Leaflet IRINOTECAN AUROBINDO 20mg / ml concentrate for solution for infusion
- Product code:
- W69253001
- Quantity:
- 1
- Indicated for:
- colorectal cancer
- Route of administration:
- infusion
- Substance:
- irinotecan (topoisomerase inhibitor)
- ATC
- L01CE02 — Antineoplastic and immunomodulating agents | Plant alkaloids and other natural products | Topoisomerase 1 (TOP1) inhibitors
Precautions:
Cytotoxic / special handling
Handle with special care.
Colitis / severe diarrhea
Seek medical advice if severe or persistent diarrhea occurs.
Contraception required
Effective contraception is required during treatment.
Contraindicated during breastfeeding
Do not use this medicine while breastfeeding.
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Hepatotoxicity
This medicine may affect the liver.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Severe skin reactions
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Genetic test recommended
A genetic test may be needed before treatment.
Irinotecan is a chemotherapy medication used to treat metastatic colorectal cancer, usually in combination with other drugs. It works by inhibiting the enzyme topoisomerase I, which is essential for DNA replication in cancer cells, thereby causing their death.
The medication is administered intravenously under the supervision of an oncologist, and the dosage is adjusted based on body weight and the patient's overall condition.
Side effects may include severe diarrhea, nausea, vomiting, decreased blood cell counts, or hair loss. In rare cases, severe allergic reactions or liver toxicity may occur.
Patients should be closely monitored during treatment and inform their doctor about any other medications they are taking. Pregnant or breastfeeding women should not use this medication.
The medication is administered intravenously under the supervision of an oncologist, and the dosage is adjusted based on body weight and the patient's overall condition.
Side effects may include severe diarrhea, nausea, vomiting, decreased blood cell counts, or hair loss. In rare cases, severe allergic reactions or liver toxicity may occur.
Patients should be closely monitored during treatment and inform their doctor about any other medications they are taking. Pregnant or breastfeeding women should not use this medication.
General data about IRINOTECAN AUROBINDO 20mg / ml
- Substance:
- irinotecan
- Date of latest medicines list:
- 01-12-2022
- Product code:
- W69253001
- Concentration:
- 20mg / ml
- Pharmaceutical form:
- concentrate for solution for infusion
- Quantity:
- 1
- Product type:
- Generic medicine
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for irinotecan
Concentrations available for irinotecan
- 1.5mg/ml
- 20mg/ml
- 4.3mg/ml